Clinical Research Study Finder

Children's Hospital of Philadelphia leads or participates in hundreds of clinical research studies and clinical trials. Many of the studies that are currently enrolling patients can be found in this database. Use this finder to learn more about the purpose of these studies and clinical trials, find out who can participate, and tell us you're interested in enrolling.

Find a Clinical Research Study

181 - 187 of 187

Executive Function and Healthcare Transition in IMD

Inherited Metabolic Disorders (IMD) are single gene conditions that affect metabolic pathways. IMD are individually rare, but collectively common. Advances in diagnosis and management have greatly increased the life expectancy of patients with IMD. Gaps in our knowledge about adult neurocognitive outcomes and quality of life confounds the ability to obtain critical therapeutic supports, including social services and vocational rehabilitation. The lack of information also complicates our ability to provide anticipatory guidance to the families of younger patients about prognosis and how to optimize outcome. This study examines neurocognitive outcomes for adults with IMD with a focus on executive and adaptive function, domains necessary for managing life skills, using an entirely remote format.

Participants in this study will complete online surveys on their life skills, medical self-management skills, and quality of life. Thinking skills will be assessed through online questionnaires and a web-based collection of games that test executive function. Some participants will be asked to take part in an interview about their experience as an adult and the transition from pediatric to adult-centered healthcare. 

Lurbinectedin in Ewing Sarcoma

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Neoneur feeding system

Safe oral feeding is a particular challenge for premature infants and those born with complex congenital heart disease (CHD). Safe oral feeding requires coordination of oral cavity changes with respiration. Neoneur is a novel hand-held mobile device which innovatively measures patterns of oral cavity pressure synchronized with respiration, providing a quantitative assessment of feeding skills. Infants will be fed with the Neoneur device 2-3 times a week from the initiation of oral feeding until discharge by a speech and language pathologist. The feeding assessment takes place during routine feeding, with no changes made to the feeding care plan. 

Autism Quality of Life

The purpose of this research study is to test how well a common, standardized quality of life tool measures quality of life among children on the autism spectrum who are minimally verbal or have an intellectual disability. Parents/ caregivers of autistic children (ages 5-17) who are minimally verbal or have an intellectual disability are eligible to participate in the study.

About 35% of children on the autism spectrum also have an intellectual disability, so it is important to include families with autistic children who are minimally verbal and/or have intellectual disability in research.

22CT015: CART 19-22 co-administration

CAR T cell therapy has shifted the treatment landscape for pediatric and young adult patients with advanced B-cell leukemias. This study aims to treat patients with relapsed disease by administering two CART cell products, huCART19 and CART22-65s. The study will determine the safety and efficacy and usefulness of administering two CAR T cell products in patients with advanced B-cell leukemias.

This is a Phase 1/2b trial for the treatment of patients with either advanced or refractory B cell Acute Lymphoblastic Leukemia or B-lineage lymphoblastic lymphoma. Possible procedures include medical record review, apheresis, huCART19 infusion, blood draws, physical exams, imaging, and disease assessments through bone marrows and lumbar punctures. Overall, approximately 93 subjects will be enrolled on this clinical trial.

Cannabidiol Oral Solution for Children and Teens with ASD

This study aims to find out if the study drug, GWP42003-P, works to improve symptoms for people with ASD. The study will also look at:

  • The safety of the study drug
  • What the study drug does to the body, and
  • The quality of life of your parent/legal guardian
This is a Phase 2 study, which means that although the study drug has already been tested in other people, it has not been tested in people with ASD. 

To participate in this study, you (or your child) must: 
  • Be 6 to 17 years old
  • Have an autism diagnosis 
  • Have a parent or guardian able to participate as a study partner during the entire study. The study partner will need to attend every visit and answer questionnaires about the child. 
  • Be able to swallow the liquid solution. 

Other eligibility criteria apply. 

Social Processes in Adolescent Anorexia Nervosa

The purpose of this study is to evaluate social interactions in adolescents and whether changes in information can influence social behaviors. This study will focus on behavioral assessments of social processing over time in adolescents. The information collected in this study is essential for developing clinical treatments focused on addressing social processes in adolescent anorexia nervosa (AN) and to improve our understanding of social processing in adolescent AN, informing both future research and clinical care.